Tetrahydrouridine
Tier C — Watch / tradeTetrahydrouridine
Targets：CDA
Indications (approved)：Non-small cell lung cancer, Lung cancer, Sickle cell disease, Myelodysplastic syndrome, Acute myeloid leukaemia, Melanoma, Sarcoma, 生殖细胞和胚胎肿瘤
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| TETRA-001 | 51860-53-8 | 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5,6-dihydropyrimidin-2(1H)-one |
| TETRA-002 | 63257-26-1 | 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)tetrahydropyrimidin-2(1H)-one |
Frequently asked questions
What are the approved indications of Tetrahydrouridine?
Approved indications include: Non-small cell lung cancer, Lung cancer, Sickle cell disease, Myelodysplastic syndrome, Acute myeloid leukaemia, Melanoma, Sarcoma, 生殖细胞和胚胎肿瘤.
When does the Tetrahydrouridine patent expire?
No public expiry year is available for Tetrahydrouridine yet; this page updates once verified.
How many synthesis routes are recorded for Tetrahydrouridine?
1 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Tetrahydrouridine intermediates?
All intermediates in Tetrahydrouridine routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Tetrahydrouridine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21